1. About SynapCell

Since 2005, SynapCell’s mission has been to accelerate the discovery of new treatments for patients with brain disorders. True partners of the pharmaceutical industry, we unlock the potential of drug candidates in vivo with our state-of-the-art EEG platform called Cue®.
We upgrade the predictive power of rodent models with objective EEG biomarkers of neurological disorders for a smooth translation to the clinic. We study compounds’ pharmacodynamics out of any brain structure and deliver decision-enabling outcomes from off-the-shelf screening, dose-response, phenotyping, or customized exploratory protocols. Striving to advance our understanding of the brain’s pathophysiology, our team engages in authentic collaborative approach with our clients, who recognize SynapCell for its excellent quality of work from project start to finish.

2. Specific Skillsets Supporting Pharmaceutical Neuroscience

SynapCell’s cross-functional team of experts possesses know-how in:
- Stereotaxic surgery i.e. in cortical and subcortical electrodes implantation for the recording of electrophysiological activities
(electrocorticogram and local field potential),
- EEG data acquisition: recording spontaneous and evoked EEG activities,
- Signal processing,
- Data analysis and interpretation,
- Pharmacology.

3. Background Knowledge: Applications for drug discovery

- Off-the-shelf or customized assays designed for drug discovery applications.
- Functional EEG phenotyping and biomarker identification
- In vivo Pharmacological testing of neuroactive compounds in freely-moving rodents:
- Compound pharmaco-EEG profiling
- Head to head drug comparison
- Identification of a compound most effective dosing and peak time